Considering the role of four months of rifampin in the treatment of latent tuberculosis infection

In summary, with 2RZ having been curtailed due to toxicity, and because of adherence and other difficulties with the 9H regimen, there are several reasons for considering the use of 4R in the treatment of LTBI (Table 1). We argue that 4R is an effective, relatively nontoxic, affordable strategy that clinicians and program managers should consider for more widespread use in selected populations and settings to effectively and efficiently treat LTBI, thereby accelerating the decline of TB in their communities.